Merus (MRUS) Earns Buy Rating from Analysts at Guggenheim

Share on StockTwits

Guggenheim initiated coverage on shares of Merus (NASDAQ:MRUS) in a research note released on Friday, Benzinga’s Daily Ratings Newsletter reports. The brokerage issued a buy rating and a $25.00 price target on the biotechnology company’s stock.

Other equities research analysts have also issued reports about the stock. BidaskClub lowered shares of Merus from a hold rating to a sell rating in a report on Thursday, March 21st. Zacks Investment Research raised shares of Merus from a hold rating to a buy rating and set a $14.00 price target on the stock in a report on Tuesday, March 26th. Wedbush lowered their price target on shares of Merus from $34.00 to $25.00 and set an outperform rating on the stock in a report on Friday, April 5th. Citigroup decreased their price objective on shares of Merus from $18.00 to $16.00 and set a neutral rating for the company in a research report on Friday, March 15th. Finally, ValuEngine downgraded shares of Merus from a hold rating to a sell rating in a research report on Monday, February 4th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $23.00.

NASDAQ:MRUS opened at $14.72 on Friday. Merus has a one year low of $11.00 and a one year high of $26.74. The firm has a market capitalization of $308.73 million, a price-to-earnings ratio of -8.00 and a beta of -0.06.

Institutional investors have recently modified their holdings of the business. Artal Group S.A. acquired a new position in shares of Merus during the 4th quarter worth about $2,886,000. Aquilo Capital Management LLC raised its position in shares of Merus by 3.6% during the 3rd quarter. Aquilo Capital Management LLC now owns 1,295,713 shares of the biotechnology company’s stock worth $25,577,000 after purchasing an additional 44,799 shares during the last quarter. Morgan Stanley raised its position in shares of Merus by 74.3% during the 3rd quarter. Morgan Stanley now owns 71,643 shares of the biotechnology company’s stock worth $1,415,000 after purchasing an additional 30,538 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Merus by 33.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 17,723 shares of the biotechnology company’s stock worth $350,000 after purchasing an additional 4,476 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Merus by 18.8% during the 4th quarter. Geode Capital Management LLC now owns 14,987 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 2,373 shares during the last quarter. Institutional investors and hedge funds own 53.06% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

Featured Story: Does the discount rate affect the economy?

Analyst Recommendations for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Norsk Hydro ASA  Cut to “Sell” at Zacks Investment Research
Norsk Hydro ASA Cut to “Sell” at Zacks Investment Research
Zacks Investment Research Upgrades freenet  to Hold
Zacks Investment Research Upgrades freenet to Hold
Evertz Technologies  PT Raised to C$20.00 at Canaccord Genuity
Evertz Technologies PT Raised to C$20.00 at Canaccord Genuity
Boliden  Upgraded at Deutsche Bank
Boliden Upgraded at Deutsche Bank
Calian Group  Receives “Buy” Rating from Laurentian
Calian Group Receives “Buy” Rating from Laurentian
Altus Midstream  Downgraded by Zacks Investment Research
Altus Midstream Downgraded by Zacks Investment Research


 
© 2006-2019 Zolmax.